Member Board Of Directors
CurrentThrough Biocon Sdn Bhd, Biocon Biologics has set up Asia’s largest integrated insulin manufacturing and R&D facility in Malaysia with an investment of over USD 350 million. This is the largest foreign investment in biotechnology in Malaysia, reflecting Biocon Biologics’ commitment to put affordable life-changing insulins within the reach of patients across the world. Commercial operations at the facility commenced in 2016 when Biocon Biologics’ recombinant human insulin became the first locally manufactured biosimilar product approved for sale in Malaysia.As the only insulin manufacturer in Malaysia, Biocon Sdn Bhd has been able to ensure insulin self-sufficiency for Malaysia and improve insulin access while providing savings to its partner, Ministry of Health (MoH), Malaysia. Since Biocon’s entry into Malaysia in 2011, prices of human insulin have dropped by over 40% and insulinization has also improved by 30%. Delivering Affordable Innovation is at the heart of everything we do.
